InvestorsHub Logo
icon url

leenico

07/23/12 12:43 PM

#13299 RE: ripster #13296

Unless I'm misreading this, the statement in red indicates that they are planning to use existing supply channels as well as Access2Flow facilities to market the q-dots.


Solterra plans to:

a) Scale up Quantum Dot Production by applying proprietary technology licensed from Rice University for our quantum dot synthesis process and accomplishing large scale production using proprietary Micro-Reactor technology jointly developed through an agreement with Access2Flow an advanced flow chemistry consortium based in the Netherlands. These proprietary technologies enable Solterra to produce the highly desirable tetrapod quantum dots at a cost savings of greater than 75% compared to competing suppliers, and will organically supply Solterra’s requirements for quantum dots for its solar cells and other quantum dot enabled products. Additionally, Solterra intends to market these Q-Dots through various existing supply channels into various markets, including but not limited to medical diagnostics and electronics. The initial pilot scale up will take place at the Access2Flow facilities in the Netherlands and once optimized will be relocated to a solar cell production facility, which is anticipated to be located in Saudi Arabia.
icon url

DDhawk

07/23/12 4:35 PM

#13313 RE: ripster #13296

Frees post#13306...in a more cordial tone...
worth having & not to do your talking for you but...it was surely a target for the ModSquad if not toned down a bit ;)
------------------------------------------------------------------
Business Accomplishments to Date

Developed and implemented plan to establish nanobio R&D and production lab in Texas.

10K comments continued...

In addition, since revenues generated from our existing products have been modest and the products we are developing incorporate new technologies and use new installation methods, we cannot predict whether or not product liability claims will be brought against us in the future or the effect of any resulting adverse publicity on our business.